Baseline characteristics and clinical outcome according to MPV
| Characteristics | Total (n=153) | MPV <10.4 fL (n=77) | MPV ≥10.4 fL (n=76) | p Value |
|---|---|---|---|---|
| Age (years), mean (SD) | 61.7 (11.9) | 61.4 (12.5) | 62.1 (11.2) | 0.711 |
| Female, n (%) | 48 (31.4) | 22 (28.6) | 26 (34.2) | 0.452 |
| Hypertension, n (%) | 83 (54.2) | 40 (51.9) | 43 (56.6) | 0.565 |
| Diabetes mellitus, n (%) | 19 (12.4) | 9 (11.7) | 10 (13.2) | 0.783 |
| Dyslipidemia, n (%) | 6 (3.9) | 2 (2.6) | 4 (5.3) | 0.442 |
| Coronary artery disease, n (%) | 17 (11.1) | 5 (6.5) | 12 (15.8) | 0.067 |
| Current smoking, n (%) | 31 (20.3) | 23 (29.9) | 8 (10.5) | 0.003** |
| Stroke/TIA, n (%) | 16 (10.5) | 6 (7.8) | 10 (13.2) | 0.278 |
| SBP (mm Hg), mean (SD) | 147.4 (23.3) | 144.9 (22.1) | 150.0 (24.4) | 0.181 |
| DBP (mm Hg), mean (SD) | 84.7 (13.0) | 85.1 (12.4) | 84.3 (13.6) | 0.704 |
| Glucose (mmol/L), median (IQR) | 7.3 (6.1–8.6) | 6.9 (6.0–8.4) | 7.6 (6.3–8.6) | 0.124 |
| Platelet count (109/L), median (IQR), | 183.0 (156.5–234.5) | 203.0 (164.5–261.0) | 171.5 (149.3–211.5) | 0.005** |
| Leukocyte count (109/L), mean (SD) | 9.5 (3.6) | 9.4 (3.4) | 9.5 (3.8) | 0.917 |
| Neutrophil count (109/L), mean (SD) | 7.0 (3.7) | 6.8 (3.5) | 7.2 (3.9) | 0.452 |
| Lymphocyte count (109/L), mean (SD) | 1.6 (1.1–2.2) | 1.9 (1.3–2.5) | 1.4 (1.1–2.2) | 0.019* |
| MPV/platelet count, median (IQR) | 0.06 (0.04–0.07) | 0.05 (0.04–0.06) | 0.06 (0.05–0.08) | 0.000** |
| Baseline NIHSS score, mean (SD) | 15.1 (4.9) | 15.2 (5.3) | 14.9 (4.4) | 0.680 |
| IV thrombolysis, n (%) | 51 (33.3) | 26 (33.8) | 25 (32.9) | 0.909 |
| Onset to groin puncture time (min), mean (SD) | 258.5 (73.3) | 255.2 (73.5) | 261.9 (73.4) | 0.578 |
| Total time of operation (min), median (IQR) | 120.0 (86.0–152.5) | 120.0 (81.0–157.5) | 119.5 (90.0–150.0) | 0.994 |
| Vessel occlusion site, n (%) | ||||
| ICA | 56 (36.6) | 25 (32.5) | 31 (40.8) | 0.285 |
| M1 | 79 (51.6) | 44 (57.1) | 35 (46.1) | 0.170 |
| M2 | 14 (9.2) | 5 (6.5) | 9 (11.8) | 0.251 |
| TOAST classification, n (%) | ||||
| Large-artery atherosclerosis | 70 (45.8) | 38 (49.4) | 32 (42.1) | 0.368 |
| Cardioembolic | 58 (37.9) | 24 (31.2) | 34 (44.7) | 0.084 |
| Other or undetermined | 25 (16.3) | 15 (19.5) | 10 (13.2) | 0.290 |
| mTICI 2b/3, n (%) | 80 (52.3) | 47 (61.0) | 33 (43.4) | 0.029* |
| PH 1, n (%) | 16 (10.5) | 9 (11.7) | 7 (9.2) | 0.617 |
| PH 2, n (%) | 24 (15.7) | 11 (14.3) | 13 (17.1) | 0.631 |
| Symptomatic ICH, n (%) | 11 (7.2) | 4 (5.2) | 7 (9.2) | 0.336 |
| Clinical outcome at 3 months, n (%) | ||||
| mRS (0–2) | 66 (43.1) | 44 (57.1) | 22 (28.9) | 0.000** |
| Mortality | 40 (26.1) | 16 (20.8) | 24 (31.6) | 0.129 |
*p<0.05, **p<0.01.
DBP, diastolic blood pressure; ICA, internal carotid artery; ICH, intracerebral hemorrhage; M1/M2, M1/M2 segment of the middle cerebral artery; MPV, mean platelet volume; mRS, modified Rankin Scale; mTICI, modified Treatment in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; PH, parenchymal hematoma; SBP, systolic blood pressure; TIA, transient ischemic attack; TOAST, Trial of Org 10 172 in Acute Stroke Treatment.